CRBU News and Press, Caribou Biosciences Inc. From 09/23/23

2023-09-23 08:45:00 ET In our modern age, the power of gene editing is undeniable. After years of foundational scientific research, it's now becoming possible to treat illnesses that were until very recently intractable. And (as is usually the case during periods of great innovation), there...

2023-09-22 15:00:17 ET More on the markets No Signs Of A Major Top Yet, Staying Long BofA strategists have changed their view of the S&P 500 target, up 4%. Quant stock news sentiment measure keeps improving - BofA Amazon, Disney, Boeing boosted in Wells F...

2023-09-19 08:00:00 ET Summary Caribou Biosciences shows promise with a 94% overall response rate in Phase 1 trials for CB-010, but faces a competitive CAR-T landscape. Financially robust with $292.5M liquid assets, but concerns arise from increasing R&D costs and declining li...

2023-08-08 17:19:01 ET Caribou Bioscience press release ( NASDAQ: CRBU ): Q2 GAAP EPS of -$0.48 beats by $0.01 . Revenue of $3.76M (-10.3% Y/Y) beats by $0.69M . For further details see: Caribou Bioscience GAAP EPS of -$0.48 beats by $0.01, revenue of $3....

-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1 trial enrollment continues in r/r MM -- -- CB-012 IND application submission fo...

2023-07-28 08:30:00 ET With shares of Caribou Biosciences (NASDAQ: CRBU) up by 51% in the past 30 days, there's more than one reason why you might want to consider a purchase for yourself. Between its recent release of some great early-stage data from its flagship program and its po...

2023-07-22 09:45:00 ET What does "off-the-shelf" mean to you in the context of advanced cancer treatments? If you said something along the lines of "a therapy that doesn't need lots of customization for each patient before being used," you're on the right track. For biotechs like Cari...

2023-07-21 10:00:00 ET Up by 32% in the past three months, Caribou Biosciences (NASDAQ: CRBU) is a pre-revenue biotech stock with explosive potential. Per some new data released on July 13, its candidate to treat lymphoma might be a massive winner in the making. But early stage ...

2023-07-17 05:11:51 ET Summary Caribou Biosciences' results from the dose expansion portion of the phase 1 ANTLER study, using CB-010 for the treatment of patients with relapsed/refractory second-line LBCL patients, are expected in the 1st half of 2024. A $25 million equity invest...

2023-07-14 14:12:48 ET Caribou Biosciences is down 23% in Friday trading after announcing following Thursday's closing bell a $125M stock offering and phase 1 data on a non-Hodgkin's lymphoma CAR-T candidate. The offering was upsized to $150M from $125M. It was priced late Thurs...